IDO2 and neoplasm: Our efforts concentrated on developing an immune signature with prognostic ability based on the comprehensive list of immune-related genes (PD-1, PD-L1, PD-L2, IDO-1, IDO-2 and INFγ) and then examining gene expression in the tumor microenvironment.